The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
Context: Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels. Objective: To characte...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2020-06-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/9/6/EC-20-0173.xml |
| _version_ | 1811295796262338560 |
|---|---|
| author | Zeeshan Javed Maria Papageorgiou Leigh A Madden Alan S Rigby Eric S Kilpatrick Stephen L Atkin Thozhukat Sathyapalan |
| author_facet | Zeeshan Javed Maria Papageorgiou Leigh A Madden Alan S Rigby Eric S Kilpatrick Stephen L Atkin Thozhukat Sathyapalan |
| author_sort | Zeeshan Javed |
| collection | DOAJ |
| description | Context: Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels.
Objective: To characterise and compare the effects of empagliflozin vs metf ormin on the circulating levels of EMPs in overweight/obese women with PCOS.
Methods: This was a randomised, comparative, 12-week single-centre trial conducted at the Academic Diabetes, Endocrinology and Metabolism Research Centre, Hull, UK. This analysis includes data from 39 overweight/obese women with PCOS who completed the study and were randomised to empagliflozin (15 mg/day) (n = 19) or metformin (1500 mg/day) (n = 20). Blood samples were collected at baseline and 12 weeks after treatment and analysed for specific surface proteins (ICAM-1, VCAM-1, PECA M-1, E-selectin and endoglin) expressed by circulating EMPs using flow cytometry.
Results: In the empagliflozin group, ICAM-1 (P = 0.006), E-selectin (P = 0.016) and VCAM-1 (P = 0.001) EMPs increased significantly following 12 weeks of treatment, but no changes were seen in PECAM-1 (P = 0.93) or endoglin (P = 0.13) EMPs. In the metformin group, VCAM-1 EMPs (P < 0.001) increased significantly after 12 weeks of treatment, w hereas all other EMPs remained unchanged. When data were expressed as percentage change from baseline in each group, no significant differences were seen between groups for any biomarker (P-values from 0.22 to 0.80).
Conclusions: Short-term administration of empagliflozin and metformin in ove rweight/ obese women with PCOS appear to increase EMPs expressed by endothelial cells during their activation. |
| first_indexed | 2024-04-13T05:37:52Z |
| format | Article |
| id | doaj.art-d07cc685bfd14f86847e259bf5f87386 |
| institution | Directory Open Access Journal |
| issn | 2049-3614 2049-3614 |
| language | English |
| last_indexed | 2024-04-13T05:37:52Z |
| publishDate | 2020-06-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-d07cc685bfd14f86847e259bf5f873862022-12-22T03:00:12ZengBioscientificaEndocrine Connections2049-36142049-36142020-06-0196563569https://doi.org/10.1530/EC-20-0173The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndromeZeeshan Javed0Maria Papageorgiou1Leigh A Madden2Alan S Rigby3Eric S Kilpatrick4Stephen L Atkin5Thozhukat Sathyapalan6Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK; Department of Endocrinology and Diabetes, Pakistan Kidney and Liver Institute and Research Centre, Knowledge City, Lahore, PakistanDepartment of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK; Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, SwitzerlandSchool of Life Sciences, University of Hull, Hull, UKHull York Medical School, University of Hull, Hull, UKDepartment of Pathology, Sidra Medical and Research Center, Doha, QatarRoyal College of Surgeons in Ireland, Al Sayh, BahrainDepartment of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UKContext: Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managing PCOS affect EMP levels. Objective: To characterise and compare the effects of empagliflozin vs metf ormin on the circulating levels of EMPs in overweight/obese women with PCOS. Methods: This was a randomised, comparative, 12-week single-centre trial conducted at the Academic Diabetes, Endocrinology and Metabolism Research Centre, Hull, UK. This analysis includes data from 39 overweight/obese women with PCOS who completed the study and were randomised to empagliflozin (15 mg/day) (n = 19) or metformin (1500 mg/day) (n = 20). Blood samples were collected at baseline and 12 weeks after treatment and analysed for specific surface proteins (ICAM-1, VCAM-1, PECA M-1, E-selectin and endoglin) expressed by circulating EMPs using flow cytometry. Results: In the empagliflozin group, ICAM-1 (P = 0.006), E-selectin (P = 0.016) and VCAM-1 (P = 0.001) EMPs increased significantly following 12 weeks of treatment, but no changes were seen in PECAM-1 (P = 0.93) or endoglin (P = 0.13) EMPs. In the metformin group, VCAM-1 EMPs (P < 0.001) increased significantly after 12 weeks of treatment, w hereas all other EMPs remained unchanged. When data were expressed as percentage change from baseline in each group, no significant differences were seen between groups for any biomarker (P-values from 0.22 to 0.80). Conclusions: Short-term administration of empagliflozin and metformin in ove rweight/ obese women with PCOS appear to increase EMPs expressed by endothelial cells during their activation.https://ec.bioscientifica.com/view/journals/ec/9/6/EC-20-0173.xmlendothelial microparticlespolycystic ovary syndromesglt2 inhibitorsempagliflozinmetformin |
| spellingShingle | Zeeshan Javed Maria Papageorgiou Leigh A Madden Alan S Rigby Eric S Kilpatrick Stephen L Atkin Thozhukat Sathyapalan The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome Endocrine Connections endothelial microparticles polycystic ovary syndrome sglt2 inhibitors empagliflozin metformin |
| title | The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome |
| title_full | The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome |
| title_fullStr | The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome |
| title_full_unstemmed | The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome |
| title_short | The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome |
| title_sort | effects of empagliflozin vs metformin on endothelial microparticles in overweight obese women with polycystic ovary syndrome |
| topic | endothelial microparticles polycystic ovary syndrome sglt2 inhibitors empagliflozin metformin |
| url | https://ec.bioscientifica.com/view/journals/ec/9/6/EC-20-0173.xml |
| work_keys_str_mv | AT zeeshanjaved theeffectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT mariapapageorgiou theeffectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT leighamadden theeffectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT alansrigby theeffectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT ericskilpatrick theeffectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT stephenlatkin theeffectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT thozhukatsathyapalan theeffectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT zeeshanjaved effectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT mariapapageorgiou effectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT leighamadden effectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT alansrigby effectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT ericskilpatrick effectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT stephenlatkin effectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome AT thozhukatsathyapalan effectsofempagliflozinvsmetforminonendothelialmicroparticlesinoverweightobesewomenwithpolycysticovarysyndrome |